MedTrace Logo

Lung Cancer Organoids and Patient Derived Tumor Xenografts

NCT05092009 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2025-07-15

No results posted yet for this study

Summary

Extra tissue will be taken from patient during a procedure in standard of care. Also, through an existing line, 10ml of extra blood will be drawn. From this material the investigator will try to establish matched normal and primary human lung cancer organoids.

Conditions

Interventions

OTHER

Tissue and blood

Tissue and blood will be derived from patient during a standard of care procedure

Sponsors & Collaborators

  • Maastricht Radiation Oncology

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-05
Primary Completion
2026-04-01
Completion
2028-04-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05092009 on ClinicalTrials.gov